Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Horizon Pharma

- PMLiVE

Second time lucky for Takeda’s obesity drug

FDA approves Contrave three years after initial rejection

- PMLiVE

FDA panel votes against Actavis hypertension combo

Places a question mark over the combination of Bystolic and Diovan

- PMLiVE

Liraglutide seems effective in obesity, says FDA reviewer

Novo Nordisk drug is already successful diabetes treatment

- PMLiVE

Merck brings first PD-1 inhibitor to US market

FDA approves Keytruda for advanced melanoma

- PMLiVE

Drug regulators collaborate to tackle Ebola outbreak

EMA and FDA team up with global partners to accelerate access to medicines

- PMLiVE

UCB wins new epilepsy indication for Vimpat in the US

FDA approves drug as monotherapy in patients with partial-onset seizures

- PMLiVE

Amgen claims first-to-file spot in PCSK9 inhibitor race

Evolocumab is part of new class of treatment to tackle high cholesterol

- PMLiVE

Rapid review for Pfizer’s superbug vaccine

FDA to expedite assessment of Clostridium difficile inoculation

- PMLiVE

Amgen gets priority review for chronic heart failure hope

Raises expectations for early entry onto US market for ivabradine

- PMLiVE

FDA approves BMS/Pfizer’s Eliquis in DVT and PE

New blood clot indication puts drug on a level with rival oral anticoagulants

- PMLiVE

FDA gives green light to Genzyme’s oral Gaucher drug

Oral therapy Cerdelga is set to complement intravenous Cerezyme

- PMLiVE

‘Tentative’ US approval for Lilly/Boehringer’s Lantus copy

Full FDA recommendation for insulin is dependent on lawsuit filed by Sanofi

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links